Melissa Johnson, MD, program director of lung cancer research at Sarah Cannon Research Institute, outlines the importance of diverse patient populations in cancer trials. We need to make sure the ...

Blocking TIGIT, a T-cell immunoreceptor, benefits patients with non–small lung cancer in that it can restore their immune system’s antitumor response, leading to a greater objective response and ...

NASHVILLE, Tenn.--(BUSINESS WIRE)--Today, Sarah Cannon announced the promotion of Melissa Johnson, MD, to Program Director of Lung Cancer Research. In her new role, Dr. Johnson will lead the lung ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adding ...